Page last updated: 2024-12-06

2-methoxyestradiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-methoxy-17beta-estradiol : A 17beta-hydroxy steroid, being 17beta-estradiol methoxylated at C-2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID66414
CHEMBL ID299613
CHEBI ID28955
SCHEMBL ID8796
MeSH IDM0079449

Synonyms (100)

Synonym
MLS001076279
HY-12033
2-meoe2
pulmolar
smr000058478
panzem
MLS000028819 ,
2me2
nsc-659853
panzem ncd
2-methoxy-estra-1,3,5(10)-triene-3,17beta-diol
LMST02010035
EU-0100739
CHEBI:28955 ,
2-methoxyestradiol, powder
nsc 659853
2-methoxyestradiol ,
SMP2_000045
LOPAC0_000739
2-methoxyoestradiol
1,3,5(10)-estratrien-2,3,17-beta-triol 2-methyl ether
2-methoxyestra-1,3,5(10)-triene-3,17beta-diol
estra-1,3,5(10)-triene-3,17beta-diol, 2-methoxy-
estradiol, 2-methoxy-
estra-1(10),2,4-triene-3,17-diol, 2-methoxy-, (17beta)-
estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (17beta)-
2-hydroxyestradol 2-methyl ether
(17beta)-2-methoxyestra-1,3,5(10)-triene-3,17-diol
2-methoxy-17beta-estradiol
362-07-2
2-methoxyestradiol-17beta
C05302
(17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol
M 6383 ,
B3C40B85-1733-48FE-8418-A39011910D19
2-hydroxyestradiol 2-methyl ether
NCGC00094082-04
CHEMBL299613 ,
(8r,9s,13s,14s,17s)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
bdbm50060957
NCGC00094082-03
HMS3262C20
unii-6i2qw73sr5
6i2qw73sr5 ,
ccris 9405
BCP9000109
2-methoxy-estradiol
2-methoxyestradiol (2-meoe2)
CCG-204824
2-me2
HMS2230L22
LP00739
(17.beta.)-2-methoxyestra-1,3,5(10)-triene-3,17-diol
2-methoxyoestradiol [mart.]
2-methoxyestradiol [who-dd]
1LHW
CS-0176
S1233
AKOS015901723
diethyl1,2,3,6-tetrahydropyridazine-1,2-dicarboxylate
DB02342
MLS006010142
SCHEMBL8796
2-methoxy-1,3,5 (10)-estratriene-3,17beta-diol
AB00639611-09
tox21_500739
NCGC00261424-01
(17?)-2-methoxyestra-1,3,5(10)-triene-3,17-diol
(17?)-2-methoxyestra-1(10),2,4-triene-3,17-diol
estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (17b)-
estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (17.beta.)-
estra-1,3,5(10)-triene-3,17.beta.-diol, 2-methoxy-
2-methoxyestra-1,3,5(10)-triene-3,17-diol #
(8r,9s,13s,14s,17s)-2-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthrene-3,17-diol
AC-32086
M2530
2-methoxy-beta-estradiol
AB00639611_10
OPERA_ID_634
mfcd00010489
DTXSID3040938
2-methoxyestradiol, analytical standard
SR-01000076000-1
sr-01000076000
BRD-K44408410-001-20-0
(14beta,17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol
Q4596897
HMS3676H22
AS-19175
BCP02076
HMS3412H22
SDCCGSBI-0050717.P002
NCGC00094082-13
C74863
17beta-2-methoxyestra-1,3,5(10)-triene-3,17-diol
BP-25393
2-methoxy 17?-estradiol
2-methoxyestradiol powder
gtpl12058
2-meo-e2

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In conclusion, sustained-release 2ME2 intravitreal implants, which can be designed to deliver potentially therapeutic vitreous levels of 2ME2 for an extended period of time, appeared to be safe in normal rabbit and effective in a rat model of CNV."( Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization.
Baffi, J; Byrnes, G; Cox, TA; Csaky, KG; Robinson, MR; Sung, C; Yuan, P, 2002
)
0.58
" Thus, 2-ME has an antitumor effect on human cervical carcinoma, and it is toxic to liver and spleen in this mouse model."( Antiproliferative activity and toxicity of 2-methoxyestradiol in cervical cancer xenograft mice.
Da, J; Fu, X; Landström, M; Li, L; Ulmsten, U,
)
0.39

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic evaluation in the rabbit showed mean 2ME2 vitreous levels within the therapeutic range for the inhibition of endothelial cell proliferation."( Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization.
Baffi, J; Byrnes, G; Cox, TA; Csaky, KG; Robinson, MR; Sung, C; Yuan, P, 2002
)
0.58
" In the present study, we have compared the pharmacokinetic profiles and metabolism of 2-MeOE2 and its sulphamoylated derivative, 2-methoxyoestradiol-bis-sulphamate (2-MeOE2bisMATE), in adult female rats."( Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents.
Chander, SK; Ireson, CR; Leese, MP; Newman, SP; Parish, D; Perera, S; Potter, BV; Purohit, A; Reed, MJ; Smith, AC, 2004
)
0.32
" Pharmacokinetic sampling was done on day 1 of cycles 1 and 2 and trough samples were obtained weekly."( A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer.
Armstrong, V; Fife, K; Horvath, D; Kolesar, J; Liu, G; Sidor, C; Staab, MJ; Sweeney, C; Treston, A; Wilding, G; Yiannoutsos, C, 2005
)
0.53
" The most active analogs were evaluated for iv and oral pharmacokinetic properties via cassette dosing in rat and in mice pharmacokinetic models."( Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol.
Agoston, GE; Hanson, AD; LaVallee, TM; Pribluda, V; Shah, JH; Suwandi, L; Treston, AM; Zhan, X, 2009
)
0.57
"ENMD-1198 is well-tolerated with a pharmacokinetic exposure profile compatible with once daily dosing."( A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
Camidge, DR; Diab, S; Eckhardt, SG; Gore, L; Gustafson, D; Leong, S; Lewis, K; Messersmith, WA; Nallapareddy, S; Sidor, C; Treston, AM; Zhou, Q, 2011
)
0.61
"The aim of the present study was to evaluate the pharmacokinetic and antitumor activity of 2-methoxyestradiol (2-ME) nanosuspension relative to 2-ME solution both in vitro and in vivo."( Pharmacokinetic evaluation and antitumor activity of 2-methoxyestradiol nanosuspension.
Du, B; Du, S; Shi, X; Wang, S; Zhang, C; Zhang, Z; Zhu, L, 2012
)
0.85
" Thus, it was demonstrated that nanoencapsulation of 2-ME2 within PEGylated PLGA nanocarrier could improve its half-life and plasma concentration and thereby increase the tumour accumulation."( Influence of surface passivation of 2-Methoxyestradiol loaded PLGA nanoparticles on cellular interactions, pharmacokinetics and tumour accumulation.
Menon, D; Nair, SV; Paul-Prasanth, B; Pillai, GJ, 2017
)
0.73

Compound-Compound Interactions

The aim of this study was to explore the effect and mechanism of pirfenidone (PFD) combined with 2-methoxyestradiol (2-ME2) perfusion through portal vein on hepatic artery hypoxia-induced hepatic fibrosis.

ExcerptReferenceRelevance
"We report the first phase I trials of 2-methoxyestradiol (2ME2, Panzem Capsules, EntreMed, Rockville, MD), alone and in combination with docetaxel, in patients with metastatic breast cancer (MBC)."( Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.
James, J; Miller, KD; Murry, DJ; Sidor, C; Sledge, GW; Storniolo, AM; Treston, AM, 2007
)
0.85
" When combined with docetaxel, three patients had significant transaminase elevations that returned to normal with continued treatment (in two of three patients)."( Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.
James, J; Miller, KD; Murry, DJ; Sidor, C; Sledge, GW; Storniolo, AM; Treston, AM, 2007
)
0.58
"2ME2, alone or in combination with docetaxel, was well tolerated in patients with MBC but systemic exposure remained below the expected therapeutic range."( Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.
James, J; Miller, KD; Murry, DJ; Sidor, C; Sledge, GW; Storniolo, AM; Treston, AM, 2007
)
0.58
" These cells were treated with 2-ME alone or in combination with paclitaxel, cisplatin, or doxorubicin."( Antiproliferative effects of 2-methoxyestradiol alone and in combination with chemotherapeutic agents on human endometrial cancer cells.
Chang, TC; Chen, CH; Chen, RJ; Chien, CH; Chow, SN; Lee, WJ, 2009
)
0.64
" We performed a prospective, phase II study of 2ME2, administered in combination with bevacizumab, in patients with advanced carcinoid tumors."( A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.
Abrams, TA; Blaszkowsky, LS; Chan, JA; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Regan, E; Sidor, C; Zhu, AX, 2011
)
0.65
" We conducted a multicenter phase II study to evaluate the objective response rate of 2-methoxyestradiol (2ME2 NCD) alone and in combination with sunitinib for patients with metastatic renal cell carcinoma who have progressed on sunitinib alone."( A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.
Arnott, J; Bruce, JY; Carducci, M; Eickhoff, J; Liu, G; Logan, T; Pili, R; Treston, A; Wilding, G, 2012
)
0.93
" Patients were treated with 2ME2 NCD alone or in combination with sunitinib."( A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.
Arnott, J; Bruce, JY; Carducci, M; Eickhoff, J; Liu, G; Logan, T; Pili, R; Treston, A; Wilding, G, 2012
)
0.7
"To detect the effects of quercetin (Que) combined with 2-methoxyestradiol (2-ME) on the proliferation of androgen-dependent LNCaP human prostate cancer cells line and androgen-independent PC-3 human prostate cancer cells line, and to evaluate the antitumor effects of different combos of the two drugs."( [Effect of 2-methoxyestradiol combined with quercetin on prostate cancer in vitro].
Song, LM; Wang, GD; Wang, HP; Xing, NZ, 2016
)
1.07
"The aim of this study was to explore the effect and mechanism of pirfenidone (PFD) combined with 2-methoxyestradiol (2-ME2) perfusion through portal vein on hepatic artery hypoxia-induced hepatic fibrosis."( Effect and mechanism of pirfenidone combined with 2-methoxy-estradiol perfusion through portal vein on hepatic artery hypoxia-induced hepatic fibrosis.
Huang, N; Jiang, QG; Lin, JQ; Yan, LY; Yang, WZ; Zheng, H, 2023
)
1.13

Bioavailability

2-Methoxyestradiol is well tolerated and, despite suboptimal plasma levels and limited oral bioavailability with this capsule formulation, still showed some anticancer activity at 1,200 mg/d.

ExcerptReferenceRelevance
" Thus, the bioavailability of 2-MeOE2 is very low, whereas for 2-MeOE2bisMATE it was 85%."( Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents.
Chander, SK; Ireson, CR; Leese, MP; Newman, SP; Parish, D; Perera, S; Potter, BV; Purohit, A; Reed, MJ; Smith, AC, 2004
)
0.32
" We have previously shown that a number of sulphamoylated analogues of 2-MeOE2 possess enhanced potency and bioavailability with respect to 2-MeOE2."( Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2-substituted oestradiol mono- and bis-3-O-sulphamates.
Leese, MP; Potter, BV; Purohit, A; Raobaikady, B; Reed, MJ, 2005
)
0.33
"2-Methoxyestradiol is well tolerated and, despite suboptimal plasma levels and limited oral bioavailability with this capsule formulation, still showed some anticancer activity at 1,200 mg/d."( A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer.
Armstrong, V; Fife, K; Horvath, D; Kolesar, J; Liu, G; Sidor, C; Staab, MJ; Sweeney, C; Treston, A; Wilding, G; Yiannoutsos, C, 2005
)
1.97
" A new formulation of 2ME2 with improved bioavailability is currently being developed."( Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
Arlen, PM; Dahut, WL; Figg, WD; Gulley, JL; Kohn, EC; Kotz, H; Lakhani, NJ; McNally, D; Nguyen, D; Parr, A; Sparreboom, A; Steinberg, SM; Venitz, J; Yang, SX, 2006
)
0.62
" A new formulation with better bioavailability will be tested soon in multiple myeloma."( Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.
Anderson, KC; Dispenzieri, A; Gertz, MA; Greipp, PR; Lacy, MQ; Rajkumar, SV; Richardson, PG; Schlossman, R; Sidor, CF; Witzig, TE, 2007
)
0.67
"A prodrug strategy was investigated to address the problem of limited aqueous solubility and the resulting limited bioavailability of the antitumor agent 2-methoxyestradiol."( Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
Agoston, GE; Cushman, M; Edsall, AB; Lu, TS; McClanahan, RH; Plum, SM; Song, W; Treston, AM, 2007
)
0.8
" The compound was orally bioavailable (31% after a single 10 mg kg(-1) dose) and resistant to metabolism."( The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer.
Chander, SK; Foster, PA; Jhalli, R; Leese, MP; Newman, SP; Parsons, MF; Potter, BV; Purohit, A; Reed, MJ, 2008
)
0.35
" However this study identified bioavailability of 2-ME(2) as a limiting factor."( Combination of 2-methoxyestradiol (2-ME2) and eugenol for apoptosis induction synergistically in androgen independent prostate cancer cells.
Alworth, WL; Chan, DC; Ganapathy, M; Ghosh, R; Kumar, AP, 2009
)
0.71
"Development of a novel formulation of anticancer drugs to improve their water-solubility and bioavailability remains a great challenge."( Therapeutic efficacy of 2-methoxyestradiol microcrystals encapsulated within polyelectrolyte multilayers.
Baker, JR; Chen, X; Shi, X; Wang, SH, 2009
)
0.66
" ENMD-1198 is an analog of 2ME2 which was developed to decrease the metabolism and increase both the bioavailability and antitumor activities of the parent molecule."( A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
Camidge, DR; Diab, S; Eckhardt, SG; Gore, L; Gustafson, D; Leong, S; Lewis, K; Messersmith, WA; Nallapareddy, S; Sidor, C; Treston, AM; Zhou, Q, 2011
)
0.61
" The results indicated that the concentrations of 2ME2 had no influence on absorption rate constant (ka) of 2ME2 and the small intestinal absorption of 2ME2 was a first-order process with passive diffusion mechanism within the concentration tested."( An investigation on intestinal absorption of a new anticancer drug, 2-methoxyestradiol.
Cui, FD; Du, B; Guo, XH; Zhang, N; Zhang, ZZ, 2009
)
0.59
" However, one main problem appears to be the bioavailability of 2ME, therefore new formulations are now in the test phase."( 2-Methoxyestradiol--biology and mechanism of action.
Mueck, AO; Seeger, H, 2010
)
1.8
" Clinical studies reflected very high inter- and intrapatient variability and oral bioavailability of 1 to 2%."( Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges.
Gerk, PM; Verenich, S, 2010
)
0.67
" In vivo release data demonstrating that 2-ME liposomes could be transported to tumor site, improved therapeutic efficacy and bioavailability of 2-ME liposomes in subcutaneous tumor chemotherapy."( In vitro and in vivo investigation of a novel two-phase delivery system of 2-methoxyestradiol liposomes hydrogel.
Chen, H; Guo, X; Li, S; Xing, Y, 2014
)
0.63
" However, due to its limited biological accessibility, synthetic analogues have been synthesized and tested in attempt to develop drugs with improved oral bioavailability and efficacy."( Sulphamoylated 2-methoxyestradiol analogues induce apoptosis in adenocarcinoma cell lines.
Joubert, A; Lafanechère, L; Martinez, A; Mqoco, T; Prudent, R; Theron, A; Vieira, W; Visagie, M, 2013
)
0.74
" In silico-design by means of receptor- and ligand molecular modeling is thus effective in improving compound bioavailability while preserving apoptotic activity in vitro."( In vitro assessment of a computer-designed potential anticancer agent in cervical cancer cells.
Jaiswal, SR; Joubert, AM; Visagie, MH, 2016
)
0.43
" After oral administration to rats, 2-ME-micelles-microspheres compared to 2-ME micelles could prolong significantly blood retention time (MRT) of 2-ME by 12 times and enhance oral absolute bioavailability from 49."( High oral bioavailability of 2-methoxyestradiol in PEG-PLGA micelles-microspheres for cancer therapy.
Chen, C; Ding, F; Guo, X; Hou, P; Hu, Y; Li, Z; Liu, X; Wang, Z; Zhang, Z, 2017
)
0.75
"The primary purpose of the present study was to design and optimize a solid lipid nanoparticle (SLN) formulation of the poorly water-soluble drug 2-methoxyestradiol (2-ME) to improve its oral bioavailability and prolong the duration of therapeutic drug level."( PEG-PCL modification and intestinal sustained-release of solid lipid nanoparticles for improving oral bioavailability of 2-methoxyestradiol.
Ding, F; Guo, X; Li, X; Liu, X; Xing, Y; Zhang, J, 2019
)
0.92
"Due to the poor solubility and bioavailability of 2-methoxyestradiol (2-ME), 2-ME emulsified drug delivery system (2-ME-SEDDS) was designed and characterized."( Preparation of 2-Methoxyestradiol Self-emulsified Drug Delivery System and the Effect on Combination Therapy with Doxorubicin Against MCF-7/ADM Cells.
He, S; Li, C; Li, T; Pan, H; Yu, C, 2022
)
1.33
" However, its poor bioavailability and rapid degradation hinder its development for clinical use."( PEGylated Polymeric Nanoparticles Loaded with 2-Methoxyestradiol for the Treatment of Uterine Leiomyoma in a Patient-Derived Xenograft Mouse Model.
Borahay, MA; Bujalowski, PJ; Enazy, SA; Kilic, G; Kirschen, GW; Motamedi, M; Oberhauser, AF; Rytting, E; Saada, J; Salama, SA; Shah, M; Vincent, K; Yang, J, 2023
)
1.17

Dosage Studied

2-ME2 was reported to elicit both stimulation and inhibition of tumor angiogenesis and growth depending on the dosage used. Tocopherols and saponins extracted from argan tree and 2-methoxyestradiol exhibit a dose-response cytotoxic effect and an antiproliferative action.

ExcerptRelevanceReference
" The dose-response of DHT was biphasic in the presence and absence of FSH, such that progesterone production in the presence of 8 micrograms/ml DHT was similar to basal progesterone production."( Comparative effects of androgens and catecholestrogens on progesterone production by porcine granulosa cells.
Hammond, JM; Spicer, LJ, 1988
)
0.27
" To uncover the mechanism, we examined the dose-response effects of 2ME(2) on growth plate chondrocytes."( Evidence that 2-methoxyestradiol suppresses proliferation and accelerates apoptosis in normal rat growth plate chondrocytes.
Sibonga, JD; Sommer, U; Turner, RT, 2002
)
0.68
" The drug induced apoptosis in all cell lines tested and in half of the primary plasma cells evaluated in a dose-response manner."( Promising preclinical activity of 2-methoxyestradiol in multiple myeloma.
Dingli, D; Rajkumar, SV; Russell, SJ; Timm, M; Witzig, TE, 2002
)
0.59
"1, 1, 4, 20, and 75 mg/kg in a 21-d dose-response study."( Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat.
Evans, GL; Green, SJ; Lotinun, S; Pribluda, VS; Sibonga, JD; Turner, RT, 2003
)
0.62
" At the low dosage of 2ME a stimulation of tumor growth was observed, whereas at the high dosage an inhibition was found."( Effect of 2-methoxyestradiol on the growth of methyl-nitroso-urea (MNU)-induced rat mammary carcinoma.
Adlercreutz, H; Berger, MR; Elger, W; Lippert, TH; Mueck, AO; Seeger, H, 2003
)
0.72
"2-Methoxyestradiol (2-ME2) was reported to elicit both stimulation and inhibition of tumor angiogenesis and growth depending on the dosage used."( 2-Methoxyestradiol exhibits a biphasic effect on VEGF-A in tumor cells and upregulation is mediated through ER-alpha: a possible signaling pathway associated with the impact of 2-ME2 on proliferative cells.
Banerjee, S; Banerjee, SK; Banerjee, SN; Saxena, NK; Sengupta, K,
)
3.02
" Studies with high dosage 2-ME2 have shown that there are only minimal reversible side effects on normal tissue."( [2-Methoxyestradiol -- a new compound for cancer treatment].
Neuhaus, P; Schumacher, G, 2006
)
1.24
" Tocopherols and saponins extracted from argan tree and 2-methoxyestradiol exhibit a dose-response cytotoxic effect and an antiproliferative action on the tested cell lines."( Tocopherols and saponins derived from Argania spinosa exert, an antiproliferative effect on human prostate cancer.
Adlouni, A; Bennani, H; Charrouf, Z; Drissi, A; Fiet, J; Giton, F, 2006
)
0.58
"Polyphenols and sterols of virgin argan oil and 2ME(2) exhibited a dose-response cytotoxic effect and antiproliferative action on the three tested cell lines."( Antiproliferative effect of polyphenols and sterols of virgin argan oil on human prostate cancer cell lines.
Adlouni, A; Bennani, H; Drissi, A; Fiet, J; Giton, F; Kheuang, L, 2007
)
0.34
" To study the dose-response patterns, we exposed denuded mouse oocytes to 2-ME during in vitro maturation."( 2-methoxyestradiol induces spindle aberrations, chromosome congression failure, and nondisjunction in mouse oocytes.
Eichenlaub-Ritter, U; Shen, Y; Sorensen, R; Tinneberg, HR; Vogt, E; Winterscheidt, U, 2007
)
1.78
" 2-MeOE2bisMATE, dosed daily for 21 days, caused a 52% reduction in tumour growth at 5 mg kg(-1) and 38% regression at 20 mg kg(-1)."( In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol.
Chander, SK; Foster, PA; Leese, MP; Newman, SP; Potter, BV; Purohit, A; Reed, MJ, 2007
)
0.34
" The potential of 4 as an orally dosed anti-tumor agent is confirmed using breast and prostate cancer xenografts."( 3,17-disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activity.
Bubert, C; Ferrandis, E; Ho, YT; Kasprzyk, PG; Leese, MP; Mahon, MF; Newman, SP; Potter, BV; Purohit, A; Reed, MJ; Regis-Lydi, S, 2007
)
0.34
" At the maximal efficacious dosing regimen (100 mg/kg/day), administration of 2ME2 resulted in total inhibition of the study parameters and prevented neovascularization into the joint."( Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis.
Fogler, WE; Moore, EG; Park, EJ; Plum, SM; Sidor, CF; Strawn, SJ, 2009
)
0.61
" Several analogs were evaluated for metabolic stability in human liver microsomes and in vivo in a rat cassette dosing model."( Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.
Agoston, GE; Hunsucker, K; LaVallee, TM; Pribluda, V; Shah, JH; Suwandi, L; Swartz, GM; Treston, AM; Zhan, XH, 2009
)
0.56
" The most active analogs were evaluated for iv and oral pharmacokinetic properties via cassette dosing in rat and in mice pharmacokinetic models."( Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol.
Agoston, GE; Hanson, AD; LaVallee, TM; Pribluda, V; Shah, JH; Suwandi, L; Treston, AM; Zhan, X, 2009
)
0.57
" Cycle 1 consisted of 28 days daily dosing followed by a 14-(Part A) or 7-(Part B) day observation period, then continuously in 28 day cycles thereafter."( A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
Camidge, DR; Diab, S; Eckhardt, SG; Gore, L; Gustafson, D; Leong, S; Lewis, K; Messersmith, WA; Nallapareddy, S; Sidor, C; Treston, AM; Zhou, Q, 2011
)
0.61
"The Ki values for probenecid inhibition of 2ME2 glucuronide formation, when compared to maximum probenecid plasma concentrations anticipated clinically, indicate that probenecid co-administration has the potential to augment systemic plasma levels of 2ME2 after oral dosage in humans."( Inhibition of 2-methoxyestradiol glucuronidation by probenecid.
Castellot, J; Greenblatt, DJ; Matin, B; Qian, Y; Sherbini, A; Zhao, Y, 2015
)
0.78
"Drug toxicity and insufficient drug dosing place a limit on the effect of chemotherapy."( Dual-modal imaging-guided theranostic nanocarriers based on 2-methoxyestradiol and indocyanine green.
Chen, H; Feng, N; Feng, Q; Huo, P; Xin, X; Xu, Y; Zhang, N; Zhang, Y; Zhang, Z, 2021
)
0.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antimitoticAny compound that inhibits cell division (mitosis).
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
angiogenesis modulating agentAn agent that modulates the physiologic angiogenesis process. This is accomplished by endogenous angiogenic proteins and a variety of other chemicals and pharmaceutical agents.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
17beta-hydroxy steroidA 17-hydroxy steroid in which the hydroxy group at position 17 has a beta-configuration.
3-hydroxy steroidAny hydroxy steroid carrying a hydroxy group at position 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Nsp9 interactions (COVID-19 Disease Map)8330
Spinal cord injury08
Estrogen metabolism025

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency50.11870.044717.8581100.0000AID485294
glp-1 receptor, partialHomo sapiens (human)Potency11.22020.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency22.77980.100020.879379.4328AID588453; AID588456
ATAD5 protein, partialHomo sapiens (human)Potency11.57740.004110.890331.5287AID493107
GLS proteinHomo sapiens (human)Potency1.58490.35487.935539.8107AID624146
PPM1D proteinHomo sapiens (human)Potency9.30050.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency2.14210.000811.382244.6684AID686978; AID686979
regulator of G-protein signaling 4Homo sapiens (human)Potency0.21190.531815.435837.6858AID504845
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency21.31680.001530.607315,848.9004AID1224819; AID1224820; AID1224821
glucocerebrosidaseHomo sapiens (human)Potency39.81070.01268.156944.6684AID2101
IDH1Homo sapiens (human)Potency2.55240.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency14.46780.035520.977089.1251AID504332; AID588346
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency39.50680.036619.637650.1187AID2100
chromobox protein homolog 1Homo sapiens (human)Potency50.11870.006026.168889.1251AID488953
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency9.20000.00419.984825.9290AID504444
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency5.84790.00669.809418.4927AID1347050
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency5.21190.00378.618923.2809AID2668
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency1.00000.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency1.00000.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency1.00000.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency6.23210.004611.374133.4983AID624296; AID624297
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency1.41250.058010.694926.6086AID602310
lamin isoform A-delta10Homo sapiens (human)Potency8.91250.891312.067628.1838AID1487
Interferon betaHomo sapiens (human)Potency9.30050.00339.158239.8107AID1347411
TAR DNA-binding protein 43Homo sapiens (human)Potency19.95261.778316.208135.4813AID652104
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency7.56860.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tubulin alpha-1A chainSus scrofa (pig)IC50 (µMol)2.20000.00672.160310.0000AID1187145
Tubulin beta chainSus scrofa (pig)IC50 (µMol)2.20000.00672.137410.0000AID1187145
Cytochrome P450 1A1Homo sapiens (human)Ki62.00000.01200.94693.8000AID1453014; AID1453015
Cytochrome P450 1B1Homo sapiens (human)Ki36.00000.00300.97417.4600AID1453015
Tubulin beta-2B chainBos taurus (cattle)IC50 (µMol)1,786.17500.25001.88388.7000AID213998; AID214009; AID214010; AID214012; AID214018; AID214035; AID214038; AID247608
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)IC50 (µMol)16.24000.25001.87798.7000AID213998; AID214009; AID214010; AID214018; AID214035
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)IC50 (µMol)19.95000.25001.86568.7000AID214009; AID214010; AID214018; AID214035
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sex hormone-binding globulinHomo sapiens (human)Kd0.00080.00020.34964.7863AID318680
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interferon gamma precursorHomo sapiens (human)AC505.80000.128015.173038.6100AID1259418; AID1259420
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (139)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1A1Homo sapiens (human)
response to hypoxiaCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
lipid hydroxylationCytochrome P450 1A1Homo sapiens (human)
fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid metabolic processCytochrome P450 1A1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A1Homo sapiens (human)
amine metabolic processCytochrome P450 1A1Homo sapiens (human)
response to nematodeCytochrome P450 1A1Homo sapiens (human)
response to herbicideCytochrome P450 1A1Homo sapiens (human)
ethylene metabolic processCytochrome P450 1A1Homo sapiens (human)
coumarin metabolic processCytochrome P450 1A1Homo sapiens (human)
flavonoid metabolic processCytochrome P450 1A1Homo sapiens (human)
response to iron(III) ionCytochrome P450 1A1Homo sapiens (human)
insecticide metabolic processCytochrome P450 1A1Homo sapiens (human)
dibenzo-p-dioxin catabolic processCytochrome P450 1A1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
response to foodCytochrome P450 1A1Homo sapiens (human)
response to lipopolysaccharideCytochrome P450 1A1Homo sapiens (human)
response to vitamin ACytochrome P450 1A1Homo sapiens (human)
response to immobilization stressCytochrome P450 1A1Homo sapiens (human)
vitamin D metabolic processCytochrome P450 1A1Homo sapiens (human)
retinol metabolic processCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
9-cis-retinoic acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
camera-type eye developmentCytochrome P450 1A1Homo sapiens (human)
nitric oxide metabolic processCytochrome P450 1A1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1A1Homo sapiens (human)
digestive tract developmentCytochrome P450 1A1Homo sapiens (human)
tissue remodelingCytochrome P450 1A1Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A1Homo sapiens (human)
response to hyperoxiaCytochrome P450 1A1Homo sapiens (human)
maternal process involved in parturitionCytochrome P450 1A1Homo sapiens (human)
hepatocyte differentiationCytochrome P450 1A1Homo sapiens (human)
cellular response to copper ionCytochrome P450 1A1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleCytochrome P450 1A1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1A1Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
microtubule-based processTubulin beta-2B chainBos taurus (cattle)
nervous system developmentTubulin beta-2B chainBos taurus (cattle)
positive regulation of axon guidanceTubulin beta-2B chainBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
androgen bindingSex hormone-binding globulinHomo sapiens (human)
protein bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingSex hormone-binding globulinHomo sapiens (human)
monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
iron ion bindingCytochrome P450 1A1Homo sapiens (human)
protein bindingCytochrome P450 1A1Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activity, acting on diphenols and related substances as donorsCytochrome P450 1A1Homo sapiens (human)
flavonoid 3'-monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxygen bindingCytochrome P450 1A1Homo sapiens (human)
enzyme bindingCytochrome P450 1A1Homo sapiens (human)
heme bindingCytochrome P450 1A1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 1A1Homo sapiens (human)
demethylase activityCytochrome P450 1A1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 1A1Homo sapiens (human)
aromatase activityCytochrome P450 1A1Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
GTPase activityTubulin beta-2B chainBos taurus (cattle)
metal ion bindingTubulin beta-2B chainBos taurus (cattle)
protein heterodimerization activityTubulin beta-2B chainBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
extracellular regionSex hormone-binding globulinHomo sapiens (human)
extracellular exosomeSex hormone-binding globulinHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A1Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
microtubule cytoskeletonTubulin beta-2B chainBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (253)

Assay IDTitleYearJournalArticle
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID304763Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv assessed as 2-methoxyestrone level after 5 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID1597199Cytotoxicity against human PC3 cells assessed as reduction in cell viability measured after 48 to 72 hrs by MTT assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID247398Concentration required to inhibit the growth of SN12C human renal cancer cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID57875Cytotoxicity against prostate DU-145 cancer cell lines.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID81509Cytotoxicity against lung HOP-62 cancer cell lines.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site.
AID621934Antiangiogenic activity in HUVEC assessed as inhibition of tube formation at 10 uM after 6 hrs by Matrigel assay2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Synthesis and antiangiogenic activity of new silybin galloyl esters.
AID69681Relative binding affinity (RBA) for estrogen receptor at 0C1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site.
AID1453014Inhibition of recombinant CYP1A1 (unknown origin) expressed in Escherichia coli DH5alphaF'Iq coexpressing human NADPH-P450 reductase using E2-d4 as substrate after 10 mins in presence of NADP+2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID469632Estrogenic activity in human MCF7 cells assessed as stimulation of cell proliferation relative to 2ME22009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Synthesis and antitumor activities of 3-modified 2-methoxyestradiol analogs.
AID452794Antiangiogenic activity against HUVECs by Brdu incorporation assay2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.
AID297653Antiproliferative activity against human DU145 cells after 96 hrs by WST1 assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
3,17-disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activity.
AID214035Evaluated for inhibition of tubulin polymerization.1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth.
AID214038In vitro inhibition of tubulin polymerization.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site.
AID1597197Cytotoxicity against human GES-1 cells assessed as reduction in cell viability measured after 48 to 72 hrs by MTT assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID89102Cytotoxicity against the cancer cell lines breast MDA-MB-4352002Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21
The effect of exchanging various substituents at the 2-position of 2-methoxyestradiol on cytotoxicity in human cancer cell cultures and inhibition of tubulin polymerization.
AID213998Inhibition of polymerization of purified bovine tubulin2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Synthesis of B-ring homologated estradiol analogues that modulate tubulin polymerization and microtubule stability.
AID1597164Antitumour activity against mouse B16 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID89628Cytotoxicity against the cancer cell lines renal SN12C2002Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21
The effect of exchanging various substituents at the 2-position of 2-methoxyestradiol on cytotoxicity in human cancer cell cultures and inhibition of tubulin polymerization.
AID302275Metabolic stability at human liver microsome assessed as UDPGT-mediated glucuronidation after 60 min2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol.
AID101633Inhibition of estrogen receptor negative MDA-MB 231 breast cancer cell proliferation at 10 uM1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Inhibition of tubulin polymerization by 5,6-dihydroindolo[2,1-alpha]isoquinoline derivatives.
AID1500950Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel 2-methoxyestradiol analogs as dual selective estrogen receptor modulators (SERMs) and antiangiogenic agents.
AID1607710Cytotoxicity against human PC3 cells after 72 hrs by CellTiter one aqueous solution assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Anti-cancer effects of cinnamon: Insights into its apoptosis effects.
AID304752Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv after 30 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID1187143Anticancer activity against human OVCAR3 cells assessed as cell growth inhibition after 5 days by MTT assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Synthesis and biological evaluations of new analogs of 2-methoxyestradiol: inhibitors of tubulin and angiogenesis.
AID304757Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv assessed as 2-methoxyestradiol level after 30 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID304756Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv assessed as 2-methoxyestradiol level after 15 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID84980In vitro inhibition of primary human umbilical vein endothelial cell (HUVEC) proliferation in presence of bFGF2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Synthesis and evaluation of a novel nonsteroidal-specific endothelial cell proliferation inhibitor.
AID89132Cytotoxicity against the cancer cell lines ovarian OVCAR-32002Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21
The effect of exchanging various substituents at the 2-position of 2-methoxyestradiol on cytotoxicity in human cancer cell cultures and inhibition of tubulin polymerization.
AID247409Concentration required to inhibit the growth of MDA-MB-435 human breast cancer cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID244799Mean graph midpoint (MGM) against a panel of human tumor cell lines2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID88793Cytotoxicity against the cancer cell lines CNS SF-5392002Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21
The effect of exchanging various substituents at the 2-position of 2-methoxyestradiol on cytotoxicity in human cancer cell cultures and inhibition of tubulin polymerization.
AID1500955Antiproliferative activity against human Ishikawa cells assessed as suppression of proliferation at 10 uM after 48 hrs by MTT assay relative to control2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel 2-methoxyestradiol analogs as dual selective estrogen receptor modulators (SERMs) and antiangiogenic agents.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID200462In vitro cytotoxicity value corresponding to 50% growth inhibition against SN12C (renal) cell line.1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth.
AID304755Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv assessed as 2-methoxyestradiol level after 5 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID317975Antiproliferative activity against human SF539 cells at2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
AID90282Mean graph midpoint for all human cancer cell line cytotoxicity.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site.
AID1500954Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel 2-methoxyestradiol analogs as dual selective estrogen receptor modulators (SERMs) and antiangiogenic agents.
AID302272Antiproliferative activity against human MDA-MB-231 cells after 48 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol.
AID304754Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv after 120 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID304742Cytotoxicity against human HOP62 cells2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID473622Antiproliferative activity against human MCF7 cells after 72 hrs by crystal violet biomass reduction assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)arylamide as a new scaffold that provides rapid access to antimicrotubule agents: synthesis and evaluation of antiproliferative activity against select cancer cell lines.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID214753In vitro cytotoxicity value corresponding to 50% growth inhibition against UACC-62(melanoma) cell line.1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth.
AID69860In vitro displacement of 0.5 nM [3H]E2 from human Estrogen receptor alpha at 10 uM2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Synthesis and evaluation of a novel nonsteroidal-specific endothelial cell proliferation inhibitor.
AID1865678Inhibition of bovine brain tubulin polymerization by spectrophotometric method2021RSC medicinal chemistry, Aug-18, Volume: 12, Issue:8
Design, synthesis and biological evaluation of combretastatin A-4 sulfamate derivatives as potential anti-cancer agents.
AID1897679Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022Bioorganic & medicinal chemistry, 12-15, Volume: 76Synthesis of estrone selenocyanate Compounds, anti-tumor activity evaluation and Structure-activity relationship analysis.
AID247608Inhibitory concentration against bovine brain tubulin polymerization2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization.
AID1597194Toxicity in nude mouse xenografted with human MCF7 cells assessed as liver edema at 45 mg/kg/day, ip administered for 21 days by HE staining analysis2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID473860Inhibition of bovine brain tubulin assembly assessed as decrease in turbidity after 20 mins2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate.
AID479368Selectivity ratio of IC50 for vincristine-resistant human HL60 cells to IC50 for human HL60 cells2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Phenylcinnamides as novel antimitotic agents.
AID214191Evaluated for % inhibition of colchicine binding to tubulin.1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth.
AID214713Inhibition of colchicine binding to tubulin1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Inhibition of tubulin polymerization by 5,6-dihydroindolo[2,1-alpha]isoquinoline derivatives.
AID297654Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by WST1 assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
3,17-disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activity.
AID1597195Toxicity in nude mouse xenografted with human MCF7 cells assessed as decrease in body weight at 45 mg/kg/day, ip administered for 21 days2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID1597213Hepatotoxicity in nude mouse xenografted with human MCF7 cells assessed as increase in serum alkaline phosphatase level at 45 mg/kg/day, ip administered for 21 days by biochemical automatic analyzer2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID247245Growth inhibitory concentration against human prostate DU-145 cancer cell line2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization.
AID473857Antiproliferative activity against human OVCAR-3 cells after 96 hrs by WST-1 assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate.
AID302276Metabolic stability at human liver cytosol assessed as sulfotransferase-mediated sulfonylation after 60 min2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol.
AID317979Antiproliferative activity against human MDA-MB-435 cells2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
AID304753Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv after 60 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID473851Antiproliferative activity against human DU145 cells after 96 hrs by WST-1 assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate.
AID469623Antiangiogenic activity against HUVEC assessed as growth inhibition after 48 hrs by WST1 assay2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol.
AID469630Antiproliferative activity against human MDA-MB-231 cells2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Synthesis and antitumor activities of 3-modified 2-methoxyestradiol analogs.
AID304759Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv assessed as 2-methoxyestradiol level after 120 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID317972Antiproliferative activity against estrogen receptor negative human MDA-MB-231 cells2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
AID304765Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv assessed as 2-methoxyestrone level after 30 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID90281Mean graph midpoint for growth inhibition of all human cancer cell lines1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth.
AID1897677Antiproliferative activity against human T47D cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022Bioorganic & medicinal chemistry, 12-15, Volume: 76Synthesis of estrone selenocyanate Compounds, anti-tumor activity evaluation and Structure-activity relationship analysis.
AID80541Cytotoxicity against colon HCT116 cancer cell lines.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site.
AID70018In vitro displacement of 0.5 nM [3H]E2 from human Estrogen receptor beta at 10 uM2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Synthesis and evaluation of a novel nonsteroidal-specific endothelial cell proliferation inhibitor.
AID304745Cytotoxicity against human UACC62 cells2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID1897676Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022Bioorganic & medicinal chemistry, 12-15, Volume: 76Synthesis of estrone selenocyanate Compounds, anti-tumor activity evaluation and Structure-activity relationship analysis.
AID247549Growth inhibitory concentration against HUVEC cancer cell line2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization.
AID452792Antiproliferative activity against human U87MG cells by Brdu incorporation assay2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.
AID247390Concentration required to inhibit the growth of SF-539 human CNS cancer cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID247387Concentration required to inhibit the growth of UACC-62 human melanoma cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID317977Antiproliferative activity against human OVCAR-3 cells2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
AID1607712Cytotoxicity against human PC3 cells at 0.5 uM after 72 hrs in presence of 41 ug/ml eugenol by CellTiter one aqueous solution assay relative to control2019European journal of medicinal chemistry, Sep-15, Volume: 178Anti-cancer effects of cinnamon: Insights into its apoptosis effects.
AID304767Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv assessed as 2-methoxyestrone level after 120 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID304743Cytotoxicity against human HCT116 cells2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID469631Antiangiogenic activity in HUVEC assessed as inhibition of cell proliferation2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Synthesis and antitumor activities of 3-modified 2-methoxyestradiol analogs.
AID1897678Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022Bioorganic & medicinal chemistry, 12-15, Volume: 76Synthesis of estrone selenocyanate Compounds, anti-tumor activity evaluation and Structure-activity relationship analysis.
AID214018Inhibition of tubulin polymerization measured at 12 uM tubulin concentration.2002Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21
The effect of exchanging various substituents at the 2-position of 2-methoxyestradiol on cytotoxicity in human cancer cell cultures and inhibition of tubulin polymerization.
AID1597211Hepatotoxicity in nude mouse xenografted with human MCF7 cells assessed as increase in serum alanine transaminase level at 45 mg/kg/day, ip administered for 21 days by biochemical automatic analyzer2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID1597168Antitumour activity against human SMMC7721 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID304760Antitumor activity against LLC cells inoculated in C57BL/6J mouse assessed as lung weight at 200 mg/kg, ip qd for 12 days2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID84979In vitro inhibition of primary human umbilical vein endothelial cell (HUVEC) proliferation at 3 uM2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Synthesis and evaluation of a novel nonsteroidal-specific endothelial cell proliferation inhibitor.
AID304750Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv after 5 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID317971Antiproliferative activity against estrogen receptor positive human MCF7 cells2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
AID1500953Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel 2-methoxyestradiol analogs as dual selective estrogen receptor modulators (SERMs) and antiangiogenic agents.
AID317974Antiproliferative activity against human HCT116 cells2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
AID81507The In vitro cytotoxicity value is the concentration corresponding to 50% growth inhibition against HOP-62 (non small cell lung) cell line.1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth.
AID247235Growth inhibitory concentration against human colon cancer HCT116 cell line2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization.
AID214012Inhibition of tubulin polymerization1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Synthesis and structure-activity profiles of A-homoestranes, the estratropones.
AID304764Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv assessed as 2-methoxyestrone level after 15 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID318680Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
AID1500951Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel 2-methoxyestradiol analogs as dual selective estrogen receptor modulators (SERMs) and antiangiogenic agents.
AID1187144Anticancer activity against human WM35 cells assessed as cell growth inhibition after 5 days by MTT assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Synthesis and biological evaluations of new analogs of 2-methoxyestradiol: inhibitors of tubulin and angiogenesis.
AID317976Antiproliferative activity against human UACC62 cells2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
AID84813In vitro inhibition of primary human umbilical vein endothelial cell (HUVEC) proliferation at 10 uM; inactive2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Synthesis and evaluation of a novel nonsteroidal-specific endothelial cell proliferation inhibitor.
AID1597198Cytotoxicity against human MGC803 cells assessed as reduction in cell viability measured after 48 to 72 hrs by MTT assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID479367Cytotoxicity against vincristine-resistant human HL60 cells after 72 hrs MTS assay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Phenylcinnamides as novel antimitotic agents.
AID1187142Anticancer activity against human K562 cells assessed as cell growth inhibition after 5 days by MTT assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Synthesis and biological evaluations of new analogs of 2-methoxyestradiol: inhibitors of tubulin and angiogenesis.
AID317980Antiangiogenic activity against HUVEC cells assessed as inhibition of proliferation2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
AID1897680Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022Bioorganic & medicinal chemistry, 12-15, Volume: 76Synthesis of estrone selenocyanate Compounds, anti-tumor activity evaluation and Structure-activity relationship analysis.
AID247396Inhibition of the growth of human breast cancer MCF-7 cells done for 2 hr at 37 degree C with compound2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID304746Cytotoxicity against human OVCAR-3 cells2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID247406Concentration required to inhibit the growth of OVCAR-3 human ovarian cancer cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID102159In vitro cytotoxicity value corresponding to 50% growth inhibition against MDA-MB-435 (breast) cell line.1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth.
AID214009Inhibition of tubulin polymerization using isolated calf brain1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Inhibition of tubulin polymerization by 5,6-dihydroindolo[2,1-alpha]isoquinoline derivatives.
AID714172Metabolic stability in rat Hepatocyte assessed as compound remaining at 1 umol/L after 2 hrs by RP-HPLC analysis2012European journal of medicinal chemistry, Mar, Volume: 49Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
AID469622Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by WST1 assay2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol.
AID469629Antiproliferative activity against human MCF7 cells after 48 hrs by WST1 assay2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol.
AID1597196Cytotoxicity against HUVEC assessed as reduction in cell viability measured after 48 to 72 hrs by MTT assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID1337728Inhibition of recombinant human CYP1B1 expressed in bacterial microsomes co-expressing P450 reductase at 3 uM using 7-ethyl-O-resorufin as substrate after 45 mins in presence of NADPH by fluorescence assay relative to control2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting cytochrome P450 (CYP) 1B1 with steroid derivatives.
AID69678Relative binding affinity (RBA) for estrogen receptor at 25 degree C1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site.
AID1597167Antitumour activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID473853Antiproliferative activity against human HOP62 cells after 96 hrs by WST-1 assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate.
AID247389Concentration required to inhibit the growth of HOP-6 human lung cancer cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID1187146Antiangiogenic activity in BAECs after 18 hrs by extracellular matrix assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Synthesis and biological evaluations of new analogs of 2-methoxyestradiol: inhibitors of tubulin and angiogenesis.
AID1597165Antitumour activity against human EC109 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID1597212Hepatotoxicity in nude mouse xenografted with human MCF7 cells assessed as increase in serum aspartate transaminase level at 45 mg/kg/day, ip administered for 21 days by automatic biochemical analyzer2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID452797Metabolic stability in human liver microsomes assessed as compound remaining at 5 uM after 30 mins by LCMS analysis relative to 0 mins2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.
AID1597166Antitumour activity against human MGC803 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID247227Growth inhibitory concentration against human lung cancer HOP-62 cell line2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization.
AID452796Metabolic stability in human liver microsomes assessed as compound remaining at 5 uM after 15 mins by LCMS analysis relative to 0 mins2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.
AID1187145Inhibition of porcine brain tubulin polymerization after 60 mins2014European journal of medicinal chemistry, Oct-06, Volume: 85Synthesis and biological evaluations of new analogs of 2-methoxyestradiol: inhibitors of tubulin and angiogenesis.
AID536411Antiproliferative activity against human SKOV3 cells expressing MDR1-6/6 by sulforhodamine B assay2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance.
AID304744Cytotoxicity against human SF539 cells2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID469620Half life in CD1 mouse at 45 mg/m'2 of body surface, po administered as single dose2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol.
AID473856Antiproliferative activity against human UACC62 cells after 96 hrs by WST-1 assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate.
AID84977In vitro inhibition of primary human umbilical vein endothelial cell (HUVEC) proliferation at 1 uM2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Synthesis and evaluation of a novel nonsteroidal-specific endothelial cell proliferation inhibitor.
AID473854Antiproliferative activity against human HCT116 cells after 96 hrs by WST-1 assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate.
AID663553Antiproliferative activity against human DU145 cells at 96 hrs by WST1 assay2012ACS medicinal chemistry letters, Jan-12, Volume: 3, Issue:1
Steroidomimetic Tetrahydroisoquinolines for the Design of New Microtubule Disruptors.
AID247253Growth inhibitory concentration against human breast MDA-MB-435 cancer cell line2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization.
AID214010Inhibition of tubulin polymerization using isolated calf brain at 26 degrees C1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Inhibition of tubulin polymerization by 5,6-dihydroindolo[2,1-alpha]isoquinoline derivatives.
AID102160Cytotoxicity against breast MDA-MB-435 cancer cell lines.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site.
AID304758Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv assessed as 2-methoxyestradiol level after 60 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID1597163Antitumour activity against human SK-N-SH cells assessed as cell growth inhibition measured after 72 hrs by SRB assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID536413Antiproliferative activity against human HeLa cells by sulforhodamine B assay2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance.
AID304751Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv after 15 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID304749Cytotoxicity against human MDA-MB-435 cells2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID536412Relative resistance, ratio of IC50 for human SKOV3 cells expressing MDR1-6/6 to IC50 for human SKOV3 cells2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance.
AID317978Antiproliferative activity against human SN12-C cells2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
AID1597182Antiangiogenic activity in chicken chorioallantoic membrane assessed as reduction in neovascularization at 50 ug/ml measured after 72 hrs by CAM assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Discovery of chalcone-modified estradiol analogs as antitumour agents that Inhibit tumour angiogenesis and epithelial to mesenchymal transition.
AID247224Growth inhibitory concentration against human CNS SF-539 cancer cell line2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization.
AID214165Compound was evaluated for inhibition of colchicine binding to tubulin in experiment II.2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Synthesis of B-ring homologated estradiol analogues that modulate tubulin polymerization and microtubule stability.
AID1249500Growth inhibition of human MCF7 cells2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
AID145429In vitro cytotoxicity value corresponding to 50% growth inhibition against OVCAR-3 (ovarian) cell line.1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth.
AID479366Cytotoxicity against human HL60 cells after 72 hrs MTS assay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Phenylcinnamides as novel antimitotic agents.
AID469618Cmax in CD1 mouse at 45 mg/m'2 of body surface, po administered as single dose2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol.
AID80538The In vitro cytotoxicity value is the concentration of the compound corresponding to 50% growth inhibition againstHCT-116 (colon) cell line.1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth.
AID200441Cytotoxicity against renal SN12C cancer cell lines.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site.
AID247248Growth inhibitory concentration against human melanoma UACC-62 cancer cell line2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization.
AID247594Growth inhibitory concentration against MDA-MB-231 cancer cell line2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization.
AID1897675Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022Bioorganic & medicinal chemistry, 12-15, Volume: 76Synthesis of estrone selenocyanate Compounds, anti-tumor activity evaluation and Structure-activity relationship analysis.
AID101635Inhibition of estrogen receptor negative MDA-MB 231 breast cancer cell proliferation at 1 uM1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Inhibition of tubulin polymerization by 5,6-dihydroindolo[2,1-alpha]isoquinoline derivatives.
AID201282Cytotoxicity against CNS SF-539 cancer cell lines.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site.
AID473624Antiproliferative activity against human U937 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)arylamide as a new scaffold that provides rapid access to antimicrotubule agents: synthesis and evaluation of antiproliferative activity against select cancer cell lines.
AID452791Antiproliferative activity against human MDA-MB-435 cells by Brdu incorporation assay2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID84975In vitro inhibition of primary human umbilical vein endothelial cell (HUVEC) proliferation at 0.01 uM2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Synthesis and evaluation of a novel nonsteroidal-specific endothelial cell proliferation inhibitor.
AID90302Tested for cytotoxicities and mean graph midpoint (MGM) for growth inhibition of all 55 human cell lines2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Synthesis of B-ring homologated estradiol analogues that modulate tubulin polymerization and microtubule stability.
AID452793Antiproliferative activity against human PC3 cells by Brdu incorporation assay2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.
AID317970Antiproliferative activity against human DU145 cells2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
AID536410Antiproliferative activity against human SKOV3 cells by sulforhodamine B assay2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance.
AID452798Metabolic stability in human liver microsomes assessed as compound remaining at 5 uM after 60 mins by LCMS analysis relative to 0 mins2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.
AID69537Relative binding affinity for estrogen receptor using a tritium labeled estrogen as the tracer and immature rat uterine cytosol1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth.
AID247405Concentration required to inhibit the growth of DU-145 human prostate cancer cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID317973Antiproliferative activity against human HOP62 cells2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
AID247400Concentration required to inhibit the growth of HCT116 human colon cancer cells by 50%2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
AID302273Antiproliferative activity against human HUVECs after 48 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol.
AID213862Inhibition activity of colchicine for tubuline polymerization to that of compound1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Synthesis and structure-activity profiles of A-homoestranes, the estratropones.
AID714173Metabolic stability in human Hepatocyte assessed as compound remaining at 1 umol/L after 2 hrs by RP-HPLC analysis2012European journal of medicinal chemistry, Mar, Volume: 49Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
AID536414Antiproliferative activity against human HeLa cells expressing tubulin 3beta by sulforhodamine B assay2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance.
AID103895Anti-proliferative activity against MCF-7 human breast cancer cells was determined by using MCF-7 plate assay2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
2-Alkylsulfanyl estrogen derivatives: synthesis of a novel class of multi-targeted anti-tumour agents.
AID90434Cytotoxicity against the cancer cell lines colon HCT1162002Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21
The effect of exchanging various substituents at the 2-position of 2-methoxyestradiol on cytotoxicity in human cancer cell cultures and inhibition of tubulin polymerization.
AID1453015Inhibition of recombinant CYP1B1 (unknown origin) expressed in Escherichia coli DH5alphaF'Iq coexpressing human NADPH-P450 reductase using E2-d4 as substrate after 10 mins in presence of NADP+2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID247215Growth inhibitory concentration against human cancer cell line2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization.
AID247244Growth inhibitory concentration against human ovarian OVCAR-3 cancer cell line2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID88950Cytotoxicity against the cancer cell lines lung HOP-622002Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21
The effect of exchanging various substituents at the 2-position of 2-methoxyestradiol on cytotoxicity in human cancer cell cultures and inhibition of tubulin polymerization.
AID214193Percentage inhibition of colchicine binding to tubulin.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site.
AID536415Relative resistance, ratio of IC50 for human HeLa cells expressing tubulin 3beta to IC50 for human HeLa cells2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance.
AID1625188Antiangiogenic activity in wild type zebrafish 24 hrs post fertilization embryos assessed as reduction in blood vessel growth at 2 uM treated for 48 hrs by alkaline phosphatase assay relative to control2019Journal of natural products, 03-22, Volume: 82, Issue:3
Antiangiogenic Activity of Compounds Isolated from Anarrhinum pedatum.
AID304747Cytotoxicity against human SN12C cells2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID267562Antiproliferative activity against human LNCaP cell line2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
SAR studies of 2-methoxyestradiol and development of its analogs as probes of anti-tumor mechanisms.
AID201311The In vitro cytotoxicity corresponding to 50% growth inhibition against SF-59 (central nervous system) cell line.1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth.
AID214164Compound was evaluated for inhibition of colchicine binding to tubulin in experiment I.2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
Synthesis of B-ring homologated estradiol analogues that modulate tubulin polymerization and microtubule stability.
AID89829Cytotoxicity against the cancer cell lines melanoma UACC-622002Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21
The effect of exchanging various substituents at the 2-position of 2-methoxyestradiol on cytotoxicity in human cancer cell cultures and inhibition of tubulin polymerization.
AID88936Cytotoxicity against the cancer cell lines prostate DU-1452002Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21
The effect of exchanging various substituents at the 2-position of 2-methoxyestradiol on cytotoxicity in human cancer cell cultures and inhibition of tubulin polymerization.
AID473858Antiproliferative activity against human SN12C cells after 96 hrs by WST-1 assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate.
AID247228Growth inhibitory concentration against human renal SN12C cancer cell line2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization.
AID473852Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by WST-1 assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate.
AID57874The In vitro cytotoxicity value corresponding to 50% growth inhibition against DU-145 (prostate) cell line.1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth.
AID145430Cytotoxicity against ovarian OVCAR-3 cancer cell lines.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site.
AID304748Cytotoxicity against human DU145 cells2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID469621AUC (0 to infinity) in CD1 mouse at 45 mg/m'2 of body surface, po administered as single dose2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol.
AID214754Cytotoxicity against melanoma UACC-62 cancer cell lines.1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site.
AID473861Displacement of [3H]colchicine from bovine brain tubulin at 5 uM after 10 mins2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate.
AID473855Antiproliferative activity against human SF539 cells after 96 hrs by WST-1 assay2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate.
AID84976IIn vitro inhibition of primary human umbilical vein endothelial cell (HUVEC) proliferation at 0.1 uM2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Synthesis and evaluation of a novel nonsteroidal-specific endothelial cell proliferation inhibitor.
AID304766Drug level in Sprague-Dawley rat plasma at 1 mg/kg, iv assessed as 2-methoxyestrone level after 60 mins2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
AID1500952Antiproliferative activity against HUVEC after 48 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel 2-methoxyestradiol analogs as dual selective estrogen receptor modulators (SERMs) and antiangiogenic agents.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (754)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (2.52)18.7374
1990's43 (5.70)18.2507
2000's332 (44.03)29.6817
2010's295 (39.12)24.3611
2020's65 (8.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.71 (24.57)
Research Supply Index6.67 (2.92)
Research Growth Index5.29 (4.65)
Search Engine Demand Index42.88 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (1.41%)5.53%
Reviews51 (6.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational3 (0.39%)0.25%
Other714 (91.66%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Open-Label, Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion Administered Orally in Patients With Recurrent or Resistant Epithelial Ovarian Cancer [NCT00400348]Phase 218 participants (Actual)Interventional2006-10-31Completed
A Single-Center, Open-Label, Phase II, Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With Protracted Oral Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme [NCT00481455]Phase 215 participants (Actual)Interventional2007-04-30Completed
Phase 2, Open-Label, Safety, and Efficacy Study of 2-Methoxyestradiol Administered to Patients With Plateau Phase or Relapsed Multiple Myeloma [NCT00592579]Phase 260 participants (Actual)Interventional2001-03-31Completed
Phase 2 Efficacy and Pharmacodynamic Study of 2-Methoxyestradiol Nanocrystal Colloidal Dispersion(Panzem® NCD) in Patients With Taxane-Refractory, Metastatic,Hormone-Refractory Prostate Cancer [NCT00394810]Phase 221 participants (Actual)Interventional2006-11-30Completed
A Phase I and Pharmacologic Study of 2-Methoxyestradiol in Patients With Advanced Solid Tumors [NCT00028821]Phase 160 participants (Actual)Interventional2002-01-31Completed
A Phase I Trial Of 2-Methoxyestradiol (2ME2), (NSC-659853) An Angiogenesis Inhibitor, In Patients With Solid Tumors [NCT00030095]Phase 10 participants Interventional2001-09-30Completed
A Single-Center, Open-Label, Phase II, Safety, Pharmacokinetic and Efficacy of Panzem Nanocrystal Colloidal Dispersion Administered Orally to Patients With Recurrent Glioblastoma Multiforme [NCT00306618]Phase 227 participants (Actual)Interventional2006-01-31Completed
A Phase 1-2 Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With rhuMAb VEGF (Bevacizumab) in Patients With Locally Advanced or Metastatic Carcinoid Tumors [NCT00328497]Phase 231 participants (Actual)Interventional2006-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]